• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email
    New Drug Application (NDA): 215153
    Company: PHATHOM PHARMACEUTICALS, INC
    • Email

    Products on NDA 215153

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    VOQUEZNA DUAL PAK AMOXICILLIN; VONOPRAZAN 500MG/20MG CAPSULE, TABLET Prescription TBD TBD No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 215153

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/03/2022 ORIG-1 Approval Type 5 - New Formulation or New Manufacturer PRIORITY Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000, 215153Orig1s000ltr.pdf

    Therapeutic Equivalents for NDA 215153

    VOQUEZNA DUAL PAK

    There are no Therapeutic Equivalents.

    Get the next $PHAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    3/13/2023$21.00Buy
    Craig Hallum
    10/21/2022$16.00Buy
    Jefferies
    5/6/2022Outperform → In-line
    Evercore ISI
    More analyst ratings

    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Karbe Frank was granted 10,500 shares, increasing direct ownership by 18% to 67,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:58:25 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cola Michael F was granted 10,500 shares, increasing direct ownership by 36% to 39,798 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:58:12 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fields Heidi was granted 10,500 shares, increasing direct ownership by 54% to 30,000 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      6/5/25 4:56:32 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care